Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause
 could have been an undiagnosed genetic disease, the so called Fabry disease. In this case
 certain fat molecules are not digested and broken down by the body - but remain in the cells.
 These fat molecules build up to dangerous levels, which start to damage the body, because
 they accumulate e.g. in the walls of the blood vessels. This accumulation in the blood
 vessels of the whole body may cause life-threatening malfunctions in the brain, inducing a
 stroke.

 The purpose of this study is to investigate the stroke rehabilitation of Fabry patients
 during different therapeutic standard approaches for stroke and for Fabry disease (if any).
 During this study, stroke patients with Fabry disease will be monitored in greater detail to
 determine whether the differences in treatment are significant for patient recovery and on
 what they depend.
In a group of young stroke patients with diagnosed Fabry disease the stroke rehabilitation
 will be investigated during different prophylactic therapeutic approaches. In this study the
 investigator will not be given any instructions on stroke and Fabry therapy.

 All patients with any etiology of stroke and a diagnosed Fabry disease submitted to the
 stroke unit of the participating centres which commit to work with the EUSI (European Stroke
 Initiative) recommendations for stroke management and diagnosis will be included into the
 study.
Inclusion Criteria:

 -  Adult patients (18 - 55 years of age) with an acute cerebrovascular event (CVE) of any
 etiology defined as patients having an ischemic stroke or transient ischemic attack

 -  Genetic diagnosis (a-galactosidase defect)of Fabry disease

 -  Written informed consent from patient

 Exclusion Criteria:

 -  No proven Fabry disease

 -  Participating in an other clinical trial with any investigational new drug or medical
 device

 -  Contraindication to any of the diagnostic procedures like e.g. MRI investigation

 -  Patient has been pretreated with Enzyme Replacement Therapy at the date of informed
 consent of sifap2